| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 88 | 2025 | 686 | 10.350 |
Why?
|
| Pancreatectomy | 38 | 2024 | 164 | 4.340 |
Why?
|
| Psoriasis | 14 | 2020 | 245 | 4.120 |
Why?
|
| Adenocarcinoma | 46 | 2024 | 1182 | 3.850 |
Why?
|
| Carcinoma, Pancreatic Ductal | 23 | 2025 | 121 | 3.780 |
Why?
|
| Pancreaticoduodenectomy | 25 | 2025 | 84 | 3.410 |
Why?
|
| Dermatologic Agents | 7 | 2019 | 73 | 2.320 |
Why?
|
| Liver Neoplasms | 17 | 2024 | 760 | 1.770 |
Why?
|
| Laparoscopy | 18 | 2023 | 782 | 1.640 |
Why?
|
| HLA-C Antigens | 3 | 2017 | 17 | 1.540 |
Why?
|
| Aged | 113 | 2025 | 19424 | 1.510 |
Why?
|
| Antibodies, Monoclonal, Humanized | 12 | 2021 | 962 | 1.450 |
Why?
|
| Ustekinumab | 4 | 2019 | 52 | 1.430 |
Why?
|
| Middle Aged | 116 | 2025 | 26347 | 1.410 |
Why?
|
| Neuroendocrine Tumors | 9 | 2023 | 124 | 1.350 |
Why?
|
| Robotic Surgical Procedures | 11 | 2024 | 322 | 1.330 |
Why?
|
| Humans | 206 | 2025 | 90640 | 1.260 |
Why?
|
| Neoplasm Staging | 33 | 2018 | 2019 | 1.250 |
Why?
|
| Postoperative Complications | 21 | 2024 | 2342 | 1.210 |
Why?
|
| Antibodies, Monoclonal | 9 | 2018 | 1397 | 1.200 |
Why?
|
| Bile Duct Neoplasms | 4 | 2021 | 95 | 1.130 |
Why?
|
| Male | 126 | 2025 | 42967 | 1.130 |
Why?
|
| Pancreatic Fistula | 7 | 2023 | 17 | 1.120 |
Why?
|
| Female | 127 | 2025 | 46894 | 1.080 |
Why?
|
| Carcinoma | 7 | 2012 | 438 | 1.080 |
Why?
|
| Retrospective Studies | 62 | 2025 | 9330 | 1.060 |
Why?
|
| Treatment Outcome | 51 | 2024 | 8379 | 0.990 |
Why?
|
| Colorectal Neoplasms | 13 | 2023 | 974 | 0.990 |
Why?
|
| Biliary Tract Neoplasms | 3 | 2012 | 34 | 0.990 |
Why?
|
| Hepatectomy | 9 | 2024 | 177 | 0.940 |
Why?
|
| Interleukin-17 | 3 | 2020 | 105 | 0.940 |
Why?
|
| Deoxycytidine | 10 | 2018 | 212 | 0.900 |
Why?
|
| Venous Thromboembolism | 3 | 2023 | 162 | 0.890 |
Why?
|
| General Surgery | 3 | 2024 | 244 | 0.880 |
Why?
|
| Aged, 80 and over | 40 | 2025 | 6816 | 0.850 |
Why?
|
| Ampulla of Vater | 4 | 2014 | 23 | 0.850 |
Why?
|
| Adult | 64 | 2024 | 26953 | 0.800 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 15 | 2023 | 2525 | 0.780 |
Why?
|
| Portal Vein | 2 | 2021 | 122 | 0.750 |
Why?
|
| Endosonography | 3 | 2015 | 100 | 0.740 |
Why?
|
| Pancreatic Diseases | 4 | 2020 | 53 | 0.740 |
Why?
|
| Length of Stay | 10 | 2024 | 757 | 0.740 |
Why?
|
| Survival Analysis | 25 | 2017 | 1500 | 0.740 |
Why?
|
| Neoadjuvant Therapy | 12 | 2025 | 388 | 0.720 |
Why?
|
| Pancreatic Cyst | 5 | 2009 | 28 | 0.710 |
Why?
|
| Rectal Neoplasms | 5 | 2007 | 129 | 0.700 |
Why?
|
| Thrombosis | 2 | 2023 | 312 | 0.700 |
Why?
|
| Biological Therapy | 1 | 2020 | 47 | 0.680 |
Why?
|
| Organizational Innovation | 2 | 2020 | 43 | 0.680 |
Why?
|
| Drug Eruptions | 1 | 2020 | 32 | 0.670 |
Why?
|
| Acrodermatitis | 1 | 2019 | 4 | 0.650 |
Why?
|
| Stents | 4 | 2021 | 416 | 0.640 |
Why?
|
| Societies, Medical | 3 | 2020 | 591 | 0.630 |
Why?
|
| Prognosis | 28 | 2025 | 3813 | 0.620 |
Why?
|
| Diffusion of Innovation | 1 | 2019 | 74 | 0.620 |
Why?
|
| Venous Thrombosis | 1 | 2021 | 260 | 0.620 |
Why?
|
| Severity of Illness Index | 10 | 2021 | 1882 | 0.610 |
Why?
|
| Survival Rate | 25 | 2025 | 1895 | 0.610 |
Why?
|
| Postoperative Hemorrhage | 3 | 2017 | 46 | 0.600 |
Why?
|
| Stomach Neoplasms | 5 | 2016 | 288 | 0.600 |
Why?
|
| Adalimumab | 2 | 2018 | 89 | 0.600 |
Why?
|
| Surgical Wound Infection | 4 | 2023 | 205 | 0.600 |
Why?
|
| Endovascular Procedures | 1 | 2021 | 299 | 0.560 |
Why?
|
| Drainage | 3 | 2015 | 166 | 0.560 |
Why?
|
| Lymph Node Excision | 8 | 2016 | 222 | 0.560 |
Why?
|
| Cholangiocarcinoma | 4 | 2021 | 81 | 0.540 |
Why?
|
| Colonic Neoplasms | 9 | 2021 | 572 | 0.540 |
Why?
|
| Dermatitis, Atopic | 2 | 2021 | 56 | 0.530 |
Why?
|
| Preoperative Care | 8 | 2017 | 400 | 0.520 |
Why?
|
| Alleles | 2 | 2017 | 1138 | 0.520 |
Why?
|
| Pancreatitis | 5 | 2015 | 87 | 0.520 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2007 | 48 | 0.510 |
Why?
|
| Biomarkers, Tumor | 12 | 2024 | 1549 | 0.510 |
Why?
|
| Learning | 1 | 2019 | 287 | 0.510 |
Why?
|
| Education, Medical | 1 | 2019 | 244 | 0.510 |
Why?
|
| Pancreas | 8 | 2023 | 254 | 0.490 |
Why?
|
| Intestinal Neoplasms | 2 | 2009 | 69 | 0.490 |
Why?
|
| Antimetabolites, Antineoplastic | 6 | 2018 | 233 | 0.490 |
Why?
|
| Risk Factors | 23 | 2023 | 5583 | 0.480 |
Why?
|
| Chemotherapy, Adjuvant | 15 | 2017 | 478 | 0.480 |
Why?
|
| Combined Modality Therapy | 17 | 2025 | 1709 | 0.480 |
Why?
|
| Mass Screening | 2 | 2015 | 643 | 0.480 |
Why?
|
| Radiotherapy, Adjuvant | 12 | 2018 | 291 | 0.480 |
Why?
|
| Mesenteric Veins | 4 | 2021 | 35 | 0.470 |
Why?
|
| Regional Health Planning | 2 | 2014 | 13 | 0.470 |
Why?
|
| Embolization, Therapeutic | 2 | 2014 | 267 | 0.460 |
Why?
|
| Hepatic Artery | 1 | 2014 | 84 | 0.450 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2015 | 99 | 0.440 |
Why?
|
| Cornified Envelope Proline-Rich Proteins | 1 | 2013 | 6 | 0.440 |
Why?
|
| Carcinoma, Papillary | 4 | 2007 | 157 | 0.440 |
Why?
|
| United States | 30 | 2025 | 7142 | 0.430 |
Why?
|
| Registries | 6 | 2017 | 812 | 0.430 |
Why?
|
| Patient Readmission | 4 | 2017 | 357 | 0.420 |
Why?
|
| Proportional Hazards Models | 11 | 2017 | 841 | 0.400 |
Why?
|
| Prospective Studies | 10 | 2023 | 4348 | 0.400 |
Why?
|
| Databases, Factual | 10 | 2017 | 875 | 0.390 |
Why?
|
| Barrett Esophagus | 5 | 2018 | 94 | 0.390 |
Why?
|
| Cohort Studies | 11 | 2020 | 2891 | 0.380 |
Why?
|
| Early Detection of Cancer | 2 | 2015 | 419 | 0.380 |
Why?
|
| Quality Indicators, Health Care | 2 | 2010 | 149 | 0.380 |
Why?
|
| Radiotherapy, Conformal | 2 | 2011 | 82 | 0.380 |
Why?
|
| Safety-Based Drug Withdrawals | 1 | 2011 | 2 | 0.380 |
Why?
|
| Follow-Up Studies | 17 | 2025 | 3698 | 0.370 |
Why?
|
| Lymph Nodes | 7 | 2016 | 553 | 0.370 |
Why?
|
| Esophageal Neoplasms | 8 | 2018 | 332 | 0.350 |
Why?
|
| Neoplasms | 9 | 2023 | 3030 | 0.350 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2018 | 402 | 0.350 |
Why?
|
| Withholding Treatment | 1 | 2011 | 117 | 0.350 |
Why?
|
| Young Adult | 12 | 2021 | 6426 | 0.340 |
Why?
|
| SEER Program | 3 | 2014 | 202 | 0.340 |
Why?
|
| Health Care Costs | 2 | 2017 | 237 | 0.340 |
Why?
|
| Carcinoid Tumor | 4 | 2002 | 45 | 0.340 |
Why?
|
| Surgeons | 3 | 2023 | 252 | 0.330 |
Why?
|
| Minimally Invasive Surgical Procedures | 6 | 2024 | 259 | 0.330 |
Why?
|
| Internship and Residency | 3 | 2024 | 1068 | 0.330 |
Why?
|
| Quality of Health Care | 2 | 2010 | 388 | 0.330 |
Why?
|
| Intestine, Small | 2 | 2009 | 299 | 0.320 |
Why?
|
| Logistic Models | 9 | 2020 | 1216 | 0.310 |
Why?
|
| Multivariate Analysis | 9 | 2019 | 982 | 0.300 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2010 | 295 | 0.300 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 2018 | 163 | 0.300 |
Why?
|
| Neoplasm, Residual | 2 | 2016 | 185 | 0.300 |
Why?
|
| Hospitals, Veterans | 1 | 2007 | 22 | 0.290 |
Why?
|
| Hospital Bed Capacity | 1 | 2007 | 20 | 0.290 |
Why?
|
| Age Factors | 5 | 2018 | 1871 | 0.290 |
Why?
|
| DNA-Binding Proteins | 1 | 2013 | 1247 | 0.280 |
Why?
|
| Incidence | 10 | 2022 | 1594 | 0.280 |
Why?
|
| Quality Improvement | 2 | 2024 | 459 | 0.270 |
Why?
|
| Hospitals | 5 | 2019 | 309 | 0.270 |
Why?
|
| Patient Selection | 4 | 2014 | 682 | 0.270 |
Why?
|
| Cholangitis | 1 | 2006 | 19 | 0.260 |
Why?
|
| Hospital Costs | 3 | 2017 | 111 | 0.260 |
Why?
|
| Fluorouracil | 10 | 2023 | 548 | 0.260 |
Why?
|
| Time Factors | 9 | 2018 | 5366 | 0.250 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2005 | 25 | 0.250 |
Why?
|
| Mutation | 5 | 2024 | 4183 | 0.250 |
Why?
|
| Delivery of Health Care | 1 | 2010 | 431 | 0.250 |
Why?
|
| Gastrectomy | 2 | 2016 | 72 | 0.240 |
Why?
|
| Simulation Training | 2 | 2024 | 100 | 0.240 |
Why?
|
| Disposable Equipment | 2 | 2015 | 21 | 0.240 |
Why?
|
| Curriculum | 3 | 2024 | 574 | 0.240 |
Why?
|
| Skin | 2 | 2020 | 590 | 0.230 |
Why?
|
| Risk Assessment | 5 | 2019 | 2338 | 0.230 |
Why?
|
| CA-19-9 Antigen | 3 | 2014 | 12 | 0.230 |
Why?
|
| Clinical Competence | 4 | 2024 | 796 | 0.230 |
Why?
|
| Liver Transplantation | 3 | 2018 | 1179 | 0.230 |
Why?
|
| Hospitals, Community | 3 | 2010 | 32 | 0.230 |
Why?
|
| Gallbladder Neoplasms | 2 | 2020 | 23 | 0.230 |
Why?
|
| Virtual Reality | 1 | 2024 | 26 | 0.220 |
Why?
|
| Drug Administration Schedule | 6 | 2017 | 866 | 0.220 |
Why?
|
| MicroRNAs | 2 | 2023 | 561 | 0.220 |
Why?
|
| Insurance Claim Review | 1 | 2004 | 45 | 0.220 |
Why?
|
| Rectum | 1 | 2004 | 149 | 0.220 |
Why?
|
| Circulating Tumor DNA | 1 | 2024 | 48 | 0.220 |
Why?
|
| Cefoxitin | 1 | 2023 | 3 | 0.220 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2023 | 11 | 0.220 |
Why?
|
| Esophagectomy | 3 | 2012 | 91 | 0.210 |
Why?
|
| Chemoradiotherapy | 3 | 2016 | 304 | 0.210 |
Why?
|
| Rectus Abdominis | 2 | 2017 | 40 | 0.210 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2023 | 16 | 0.210 |
Why?
|
| Benzoates | 4 | 2007 | 33 | 0.210 |
Why?
|
| Mortality | 1 | 2004 | 148 | 0.210 |
Why?
|
| Immunosuppressive Agents | 3 | 2021 | 984 | 0.200 |
Why?
|
| Bevacizumab | 3 | 2018 | 268 | 0.200 |
Why?
|
| Chronic Disease | 3 | 2020 | 959 | 0.200 |
Why?
|
| Diagnosis, Differential | 6 | 2015 | 1608 | 0.200 |
Why?
|
| Neoplasm Metastasis | 5 | 2013 | 1066 | 0.200 |
Why?
|
| Frailty | 1 | 2024 | 84 | 0.200 |
Why?
|
| Cecal Neoplasms | 1 | 2002 | 5 | 0.200 |
Why?
|
| Biliary Tract Diseases | 1 | 2022 | 37 | 0.200 |
Why?
|
| Ileal Neoplasms | 1 | 2002 | 9 | 0.200 |
Why?
|
| Anus Neoplasms | 3 | 2011 | 36 | 0.200 |
Why?
|
| Genotype | 2 | 2017 | 1855 | 0.190 |
Why?
|
| Endoscopy, Digestive System | 2 | 2012 | 69 | 0.190 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2001 | 7 | 0.190 |
Why?
|
| Italy | 2 | 2020 | 108 | 0.190 |
Why?
|
| Bile Ducts, Extrahepatic | 2 | 2012 | 11 | 0.190 |
Why?
|
| Situs Inversus | 1 | 2001 | 15 | 0.190 |
Why?
|
| Gastric Bypass | 1 | 2023 | 114 | 0.190 |
Why?
|
| Algorithms | 4 | 2018 | 1919 | 0.190 |
Why?
|
| Chemoradiotherapy, Adjuvant | 3 | 2018 | 36 | 0.190 |
Why?
|
| Infliximab | 3 | 2018 | 159 | 0.180 |
Why?
|
| Obesity, Morbid | 2 | 2023 | 242 | 0.180 |
Why?
|
| Eczema | 1 | 2021 | 7 | 0.180 |
Why?
|
| Anastomosis, Surgical | 5 | 2016 | 277 | 0.180 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2010 | 1286 | 0.180 |
Why?
|
| Palliative Care | 5 | 2007 | 264 | 0.180 |
Why?
|
| Sigmoidoscopy | 1 | 2001 | 36 | 0.180 |
Why?
|
| Models, Theoretical | 1 | 2004 | 493 | 0.180 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2017 | 2705 | 0.180 |
Why?
|
| Nurse Practitioners | 1 | 2001 | 30 | 0.180 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2024 | 493 | 0.180 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2020 | 56 | 0.180 |
Why?
|
| Cell Cycle | 3 | 2007 | 511 | 0.180 |
Why?
|
| Adolescent | 12 | 2021 | 9354 | 0.170 |
Why?
|
| Drug Substitution | 2 | 2018 | 27 | 0.170 |
Why?
|
| Thyroid Neoplasms | 4 | 2020 | 428 | 0.170 |
Why?
|
| Etanercept | 2 | 2018 | 33 | 0.170 |
Why?
|
| Europe | 2 | 2019 | 328 | 0.170 |
Why?
|
| Genetic Markers | 3 | 2017 | 477 | 0.170 |
Why?
|
| Robotics | 1 | 2023 | 270 | 0.170 |
Why?
|
| Surgical Oncology | 1 | 2020 | 28 | 0.170 |
Why?
|
| Chemoembolization, Therapeutic | 4 | 2009 | 35 | 0.170 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2001 | 110 | 0.170 |
Why?
|
| Biological Products | 2 | 2013 | 163 | 0.170 |
Why?
|
| Cystic Fibrosis | 1 | 2020 | 116 | 0.170 |
Why?
|
| Colonic Polyps | 2 | 2008 | 132 | 0.170 |
Why?
|
| Emergencies | 1 | 2020 | 122 | 0.170 |
Why?
|
| Personnel Selection | 1 | 2020 | 62 | 0.170 |
Why?
|
| Cancer Care Facilities | 2 | 2010 | 31 | 0.170 |
Why?
|
| Neoplasm Invasiveness | 6 | 2012 | 570 | 0.160 |
Why?
|
| Lymphatic Metastasis | 8 | 2008 | 498 | 0.160 |
Why?
|
| Specialties, Surgical | 1 | 2020 | 69 | 0.160 |
Why?
|
| Cell Proliferation | 6 | 2008 | 1695 | 0.160 |
Why?
|
| Sepsis | 1 | 2023 | 330 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2018 | 854 | 0.160 |
Why?
|
| User-Computer Interface | 1 | 2020 | 187 | 0.160 |
Why?
|
| Arachidonate 5-Lipoxygenase | 3 | 2008 | 22 | 0.160 |
Why?
|
| Steroids | 1 | 2020 | 173 | 0.160 |
Why?
|
| Interviews as Topic | 1 | 2020 | 348 | 0.160 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 129 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2014 | 1362 | 0.150 |
Why?
|
| Yttrium Radioisotopes | 2 | 2009 | 59 | 0.150 |
Why?
|
| Radiotherapy | 4 | 2012 | 318 | 0.150 |
Why?
|
| Education, Medical, Continuing | 2 | 2015 | 106 | 0.150 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 1997 | 160 | 0.150 |
Why?
|
| Conversion to Open Surgery | 1 | 2018 | 11 | 0.150 |
Why?
|
| Adenoma | 3 | 2008 | 250 | 0.150 |
Why?
|
| Propensity Score | 4 | 2020 | 154 | 0.150 |
Why?
|
| Comorbidity | 3 | 2021 | 955 | 0.150 |
Why?
|
| Liver | 2 | 2017 | 1218 | 0.150 |
Why?
|
| Thyroidectomy | 3 | 2007 | 171 | 0.150 |
Why?
|
| Gene Expression Profiling | 3 | 2018 | 1462 | 0.150 |
Why?
|
| Gene Amplification | 1 | 2018 | 135 | 0.150 |
Why?
|
| Carcinoma in Situ | 2 | 2005 | 53 | 0.150 |
Why?
|
| Reoperation | 3 | 2017 | 609 | 0.140 |
Why?
|
| Databases as Topic | 2 | 2007 | 94 | 0.140 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2024 | 168 | 0.140 |
Why?
|
| Receptors, Calcitriol | 1 | 2018 | 130 | 0.140 |
Why?
|
| Nuclear Proteins | 2 | 1999 | 728 | 0.140 |
Why?
|
| Stromal Cells | 2 | 2015 | 151 | 0.140 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 440 | 0.140 |
Why?
|
| Dyslipidemias | 1 | 2018 | 107 | 0.140 |
Why?
|
| Predictive Value of Tests | 5 | 2014 | 1747 | 0.140 |
Why?
|
| Laparotomy | 1 | 2017 | 68 | 0.140 |
Why?
|
| Receptors, Interleukin-17 | 1 | 2016 | 10 | 0.140 |
Why?
|
| Metabolic Syndrome | 1 | 2018 | 125 | 0.140 |
Why?
|
| Abdominal Wall | 1 | 2017 | 30 | 0.140 |
Why?
|
| Incidental Findings | 1 | 2017 | 99 | 0.140 |
Why?
|
| Pylorus | 2 | 2007 | 14 | 0.140 |
Why?
|
| Stomach | 2 | 2012 | 111 | 0.140 |
Why?
|
| Muscular Atrophy | 1 | 2017 | 47 | 0.130 |
Why?
|
| Antineoplastic Agents | 4 | 2016 | 2337 | 0.130 |
Why?
|
| Vascular Surgical Procedures | 1 | 2017 | 150 | 0.130 |
Why?
|
| Longitudinal Studies | 2 | 2018 | 1088 | 0.130 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 2 | 1993 | 12 | 0.130 |
Why?
|
| Disease-Free Survival | 4 | 2017 | 1170 | 0.130 |
Why?
|
| Electric Impedance | 1 | 2016 | 111 | 0.130 |
Why?
|
| Guideline Adherence | 4 | 2017 | 232 | 0.130 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 2006 | 137 | 0.130 |
Why?
|
| Drug Resistance | 1 | 2016 | 234 | 0.120 |
Why?
|
| Cell Line, Tumor | 10 | 2018 | 2609 | 0.120 |
Why?
|
| Lymphoma | 2 | 2002 | 268 | 0.120 |
Why?
|
| Gastroesophageal Reflux | 2 | 2015 | 126 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 321 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 307 | 0.120 |
Why?
|
| Academic Medical Centers | 2 | 2007 | 388 | 0.120 |
Why?
|
| Benchmarking | 2 | 2008 | 79 | 0.120 |
Why?
|
| Cell Division | 6 | 2007 | 692 | 0.120 |
Why?
|
| Membrane Proteins | 4 | 2005 | 1232 | 0.120 |
Why?
|
| Feasibility Studies | 4 | 2016 | 791 | 0.120 |
Why?
|
| Remission, Spontaneous | 1 | 2014 | 52 | 0.120 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2014 | 58 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2005 | 226 | 0.110 |
Why?
|
| Gene Frequency | 1 | 2016 | 692 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 2364 | 0.110 |
Why?
|
| Hernia, Inguinal | 1 | 2015 | 76 | 0.110 |
Why?
|
| Herniorrhaphy | 1 | 2015 | 93 | 0.110 |
Why?
|
| Operating Rooms | 1 | 2014 | 125 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2015 | 3486 | 0.110 |
Why?
|
| Neutropenia | 2 | 2011 | 216 | 0.110 |
Why?
|
| Interleukin-23 | 1 | 2013 | 57 | 0.100 |
Why?
|
| Margins of Excision | 3 | 2018 | 42 | 0.100 |
Why?
|
| Trisaccharides | 1 | 2012 | 12 | 0.100 |
Why?
|
| Immunotherapy, Active | 1 | 2012 | 15 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 3 | 2017 | 474 | 0.100 |
Why?
|
| Interleukin-12 | 1 | 2013 | 111 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1056 | 0.100 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 1993 | 367 | 0.100 |
Why?
|
| Quality Control | 1 | 2012 | 117 | 0.100 |
Why?
|
| Hemorrhage | 1 | 2014 | 290 | 0.100 |
Why?
|
| Jaundice, Obstructive | 1 | 2012 | 10 | 0.100 |
Why?
|
| Nausea | 2 | 2011 | 176 | 0.100 |
Why?
|
| Hypertension | 1 | 2018 | 746 | 0.100 |
Why?
|
| Gallbladder | 1 | 2012 | 32 | 0.100 |
Why?
|
| Radiopharmaceuticals | 2 | 2012 | 198 | 0.100 |
Why?
|
| Ischemic Preconditioning | 1 | 2012 | 37 | 0.100 |
Why?
|
| Adipocytes, White | 1 | 2012 | 6 | 0.100 |
Why?
|
| Gene Deletion | 1 | 2013 | 345 | 0.100 |
Why?
|
| Electroporation | 1 | 2012 | 58 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 1993 | 306 | 0.100 |
Why?
|
| Organoplatinum Compounds | 3 | 2017 | 94 | 0.100 |
Why?
|
| Leucovorin | 3 | 2017 | 222 | 0.100 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2012 | 72 | 0.100 |
Why?
|
| Arthritis, Psoriatic | 1 | 2012 | 34 | 0.100 |
Why?
|
| Serpins | 1 | 2012 | 32 | 0.100 |
Why?
|
| Spectrum Analysis | 1 | 2012 | 119 | 0.100 |
Why?
|
| Ablation Techniques | 1 | 2012 | 38 | 0.100 |
Why?
|
| Esophagus | 1 | 2012 | 107 | 0.100 |
Why?
|
| Nerve Growth Factors | 1 | 2012 | 63 | 0.100 |
Why?
|
| Sex Factors | 4 | 2014 | 1074 | 0.100 |
Why?
|
| Operative Time | 3 | 2017 | 151 | 0.100 |
Why?
|
| Radiology, Interventional | 1 | 2012 | 70 | 0.090 |
Why?
|
| Ultrasonography, Interventional | 1 | 2012 | 126 | 0.090 |
Why?
|
| Lipoxygenase Inhibitors | 2 | 2008 | 34 | 0.090 |
Why?
|
| Disease Progression | 5 | 2018 | 1486 | 0.090 |
Why?
|
| Photochemotherapy | 1 | 2012 | 100 | 0.090 |
Why?
|
| Arteries | 1 | 2012 | 179 | 0.090 |
Why?
|
| Microspheres | 2 | 2009 | 108 | 0.090 |
Why?
|
| Cancer Vaccines | 1 | 2012 | 159 | 0.090 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 1142 | 0.090 |
Why?
|
| Leukopenia | 1 | 2011 | 67 | 0.090 |
Why?
|
| Camptothecin | 3 | 2017 | 197 | 0.090 |
Why?
|
| Ileus | 1 | 2011 | 9 | 0.090 |
Why?
|
| Brachytherapy | 1 | 2012 | 121 | 0.090 |
Why?
|
| Abdominal Abscess | 1 | 2011 | 23 | 0.090 |
Why?
|
| Biopsy | 5 | 2009 | 1192 | 0.090 |
Why?
|
| Appointments and Schedules | 1 | 2011 | 54 | 0.090 |
Why?
|
| Chromosome Aberrations | 1 | 2012 | 384 | 0.090 |
Why?
|
| Methotrexate | 1 | 2011 | 244 | 0.090 |
Why?
|
| Immunohistochemistry | 9 | 2009 | 1806 | 0.090 |
Why?
|
| Receptors, Leukotriene B4 | 2 | 2007 | 6 | 0.090 |
Why?
|
| Treatment Failure | 2 | 2009 | 282 | 0.090 |
Why?
|
| Endoscopy | 2 | 2022 | 353 | 0.090 |
Why?
|
| Intestinal Obstruction | 1 | 2011 | 89 | 0.090 |
Why?
|
| Blood Transfusion | 2 | 2024 | 170 | 0.090 |
Why?
|
| Cyclosporine | 1 | 2011 | 239 | 0.090 |
Why?
|
| G2 Phase | 2 | 2006 | 33 | 0.090 |
Why?
|
| Health Services Needs and Demand | 1 | 2011 | 107 | 0.090 |
Why?
|
| Mucin 5AC | 1 | 2009 | 8 | 0.090 |
Why?
|
| Mucin-2 | 1 | 2009 | 12 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 243 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2024 | 419 | 0.080 |
Why?
|
| Spleen | 1 | 2011 | 433 | 0.080 |
Why?
|
| Mucin-1 | 1 | 2009 | 44 | 0.080 |
Why?
|
| Waiting Lists | 1 | 2011 | 189 | 0.080 |
Why?
|
| Pancreatic Ducts | 2 | 1999 | 31 | 0.080 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 276 | 0.080 |
Why?
|
| Learning Curve | 2 | 2022 | 20 | 0.080 |
Why?
|
| Sarcoma | 2 | 2002 | 217 | 0.080 |
Why?
|
| Polymorphism, Genetic | 1 | 2013 | 827 | 0.080 |
Why?
|
| Duodenal Neoplasms | 1 | 2009 | 19 | 0.080 |
Why?
|
| Pancreatitis, Chronic | 1 | 2010 | 61 | 0.080 |
Why?
|
| Vitamin D | 3 | 2018 | 269 | 0.080 |
Why?
|
| Safety | 2 | 2010 | 144 | 0.080 |
Why?
|
| Maximum Tolerated Dose | 2 | 2010 | 265 | 0.080 |
Why?
|
| Remission Induction | 1 | 2011 | 745 | 0.080 |
Why?
|
| Radiotherapy Dosage | 2 | 2011 | 468 | 0.080 |
Why?
|
| Illinois | 3 | 2015 | 491 | 0.080 |
Why?
|
| Ischemia | 1 | 2011 | 254 | 0.080 |
Why?
|
| DNA Methylation | 3 | 2010 | 666 | 0.080 |
Why?
|
| Breast Neoplasms | 3 | 1999 | 3020 | 0.080 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2008 | 12 | 0.080 |
Why?
|
| S Phase | 2 | 2007 | 63 | 0.080 |
Why?
|
| Research Design | 3 | 2009 | 590 | 0.080 |
Why?
|
| Animals | 11 | 2016 | 27715 | 0.080 |
Why?
|
| Chicago | 2 | 2020 | 1441 | 0.080 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2008 | 34 | 0.080 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2008 | 20 | 0.080 |
Why?
|
| Socioeconomic Factors | 2 | 2008 | 595 | 0.070 |
Why?
|
| Esophagogastric Junction | 1 | 2008 | 34 | 0.070 |
Why?
|
| Gastroscopy | 1 | 2007 | 25 | 0.070 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 476 | 0.070 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2008 | 77 | 0.070 |
Why?
|
| Apoptosis | 4 | 2008 | 1725 | 0.070 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2008 | 61 | 0.070 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2007 | 23 | 0.070 |
Why?
|
| Catheter Ablation | 1 | 2010 | 256 | 0.070 |
Why?
|
| Leukotriene Antagonists | 1 | 2007 | 25 | 0.070 |
Why?
|
| Apigenin | 1 | 2006 | 7 | 0.070 |
Why?
|
| Hemothorax | 1 | 1987 | 15 | 0.070 |
Why?
|
| Stilbenes | 1 | 2007 | 25 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2010 | 349 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2006 | 1935 | 0.070 |
Why?
|
| Hospitals, Teaching | 1 | 2007 | 118 | 0.070 |
Why?
|
| Disease Models, Animal | 2 | 2008 | 2409 | 0.070 |
Why?
|
| Quality Assurance, Health Care | 1 | 2008 | 225 | 0.070 |
Why?
|
| Workload | 2 | 2023 | 130 | 0.070 |
Why?
|
| Adenoma, Islet Cell | 2 | 2007 | 28 | 0.070 |
Why?
|
| Mitosis | 1 | 2006 | 152 | 0.070 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2007 | 127 | 0.070 |
Why?
|
| Guidelines as Topic | 1 | 2007 | 161 | 0.070 |
Why?
|
| Leukotriene B4 | 1 | 2005 | 14 | 0.060 |
Why?
|
| Depsipeptides | 1 | 2006 | 29 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2007 | 230 | 0.060 |
Why?
|
| Neoplasm Seeding | 1 | 2005 | 16 | 0.060 |
Why?
|
| Surgical Flaps | 1 | 2008 | 254 | 0.060 |
Why?
|
| Epithelium | 1 | 2006 | 323 | 0.060 |
Why?
|
| Odds Ratio | 1 | 2007 | 680 | 0.060 |
Why?
|
| Ultrasonography | 2 | 2012 | 722 | 0.060 |
Why?
|
| Phosphorylation | 4 | 2006 | 1132 | 0.060 |
Why?
|
| Cystadenocarcinoma | 2 | 1995 | 12 | 0.060 |
Why?
|
| Bariatric Surgery | 1 | 2008 | 201 | 0.060 |
Why?
|
| Blotting, Western | 4 | 2012 | 795 | 0.060 |
Why?
|
| Cyclooxygenase 2 | 1 | 2005 | 99 | 0.060 |
Why?
|
| Reference Values | 2 | 1999 | 662 | 0.060 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2007 | 274 | 0.060 |
Why?
|
| Postoperative Care | 2 | 2017 | 234 | 0.060 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2004 | 18 | 0.060 |
Why?
|
| Diagnostic Errors | 1 | 2006 | 160 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2007 | 194 | 0.060 |
Why?
|
| Actuarial Analysis | 2 | 2002 | 66 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2005 | 269 | 0.060 |
Why?
|
| Drug Synergism | 1 | 2005 | 308 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2017 | 879 | 0.060 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2005 | 220 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2004 | 298 | 0.060 |
Why?
|
| Infusions, Intra-Arterial | 2 | 2008 | 36 | 0.060 |
Why?
|
| Melanoma | 1 | 2008 | 474 | 0.060 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2004 | 129 | 0.060 |
Why?
|
| RNA, Messenger | 4 | 2018 | 2034 | 0.050 |
Why?
|
| Factor V | 1 | 2023 | 8 | 0.050 |
Why?
|
| Prothrombin | 1 | 2023 | 17 | 0.050 |
Why?
|
| Piperacillin | 1 | 2023 | 8 | 0.050 |
Why?
|
| Radiography | 1 | 2005 | 809 | 0.050 |
Why?
|
| Penicillanic Acid | 1 | 2023 | 12 | 0.050 |
Why?
|
| Demography | 1 | 2004 | 184 | 0.050 |
Why?
|
| Cholecystectomy | 1 | 2023 | 25 | 0.050 |
Why?
|
| Capillaries | 1 | 2003 | 90 | 0.050 |
Why?
|
| Protein Kinases | 2 | 1996 | 212 | 0.050 |
Why?
|
| Social Class | 1 | 2004 | 136 | 0.050 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 2023 | 26 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2006 | 1873 | 0.050 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2024 | 83 | 0.050 |
Why?
|
| Cyclin A | 3 | 2007 | 29 | 0.050 |
Why?
|
| Hyaluronan Receptors | 1 | 2002 | 38 | 0.050 |
Why?
|
| Hyperparathyroidism | 1 | 2002 | 67 | 0.050 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2022 | 31 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2008 | 601 | 0.050 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2023 | 82 | 0.050 |
Why?
|
| Colectomy | 3 | 2008 | 175 | 0.050 |
Why?
|
| Carcinoembryonic Antigen | 2 | 1999 | 40 | 0.050 |
Why?
|
| Parathyroid Neoplasms | 1 | 2002 | 60 | 0.050 |
Why?
|
| Parathyroidectomy | 1 | 2002 | 80 | 0.050 |
Why?
|
| Bile | 1 | 2022 | 60 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2017 | 591 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 3 | 2008 | 303 | 0.050 |
Why?
|
| Bone Neoplasms | 1 | 2004 | 321 | 0.050 |
Why?
|
| Cardiac Surgical Procedures | 1 | 1987 | 482 | 0.050 |
Why?
|
| Cadherins | 1 | 2002 | 164 | 0.050 |
Why?
|
| Biopsy, Needle | 2 | 2009 | 233 | 0.050 |
Why?
|
| Cell Cycle Proteins | 2 | 2006 | 399 | 0.050 |
Why?
|
| Thymidylate Synthase | 1 | 2001 | 13 | 0.050 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2001 | 69 | 0.050 |
Why?
|
| Credentialing | 1 | 2001 | 14 | 0.050 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2001 | 23 | 0.050 |
Why?
|
| Consensus | 1 | 2023 | 371 | 0.050 |
Why?
|
| Marketing of Health Services | 1 | 2001 | 15 | 0.050 |
Why?
|
| DNA, Neoplasm | 2 | 2006 | 266 | 0.050 |
Why?
|
| Cisplatin | 3 | 2011 | 599 | 0.050 |
Why?
|
| Midwestern United States | 1 | 2001 | 83 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2000 | 187 | 0.040 |
Why?
|
| United Kingdom | 1 | 2020 | 167 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2002 | 354 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2009 | 2019 | 0.040 |
Why?
|
| Biological Specimen Banks | 1 | 2020 | 68 | 0.040 |
Why?
|
| Sequence Deletion | 1 | 2020 | 205 | 0.040 |
Why?
|
| Surgical Procedures, Operative | 2 | 2011 | 208 | 0.040 |
Why?
|
| Leiomyomatosis | 1 | 2000 | 12 | 0.040 |
Why?
|
| Florida | 1 | 2020 | 60 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2000 | 419 | 0.040 |
Why?
|
| Pharyngeal Neoplasms | 1 | 1999 | 15 | 0.040 |
Why?
|
| Morbidity | 1 | 2020 | 151 | 0.040 |
Why?
|
| Untranslated Regions | 1 | 2019 | 18 | 0.040 |
Why?
|
| Bronchi | 1 | 2020 | 230 | 0.040 |
Why?
|
| Nuclear Matrix-Associated Proteins | 1 | 1999 | 13 | 0.040 |
Why?
|
| Antigens, Nuclear | 1 | 1999 | 25 | 0.040 |
Why?
|
| ROC Curve | 2 | 2014 | 781 | 0.040 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 1999 | 38 | 0.040 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 1999 | 39 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2022 | 440 | 0.040 |
Why?
|
| Open Reading Frames | 1 | 2019 | 121 | 0.040 |
Why?
|
| Immunoassay | 1 | 1999 | 93 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2020 | 118 | 0.040 |
Why?
|
| Genetic Counseling | 1 | 1999 | 102 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 311 | 0.040 |
Why?
|
| Pharmacogenomic Testing | 1 | 2019 | 95 | 0.040 |
Why?
|
| Class II Phosphatidylinositol 3-Kinases | 1 | 2018 | 9 | 0.040 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2020 | 267 | 0.040 |
Why?
|
| Autoantigens | 1 | 1999 | 132 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2009 | 303 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2009 | 360 | 0.040 |
Why?
|
| Flow Cytometry | 3 | 2007 | 695 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 73 | 0.040 |
Why?
|
| Gastrointestinal Diseases | 1 | 1999 | 151 | 0.040 |
Why?
|
| Filgrastim | 1 | 2017 | 58 | 0.040 |
Why?
|
| Receptor, Notch1 | 1 | 2018 | 94 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 3 | 2008 | 1049 | 0.040 |
Why?
|
| Neoplasms, Second Primary | 1 | 2000 | 240 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 806 | 0.040 |
Why?
|
| Cryosurgery | 1 | 1998 | 58 | 0.040 |
Why?
|
| Radiography, Abdominal | 1 | 2017 | 70 | 0.040 |
Why?
|
| Blood Loss, Surgical | 1 | 2017 | 117 | 0.030 |
Why?
|
| Incisional Hernia | 1 | 2017 | 17 | 0.030 |
Why?
|
| Prolactinoma | 1 | 1997 | 8 | 0.030 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 2 | 2007 | 16 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 1998 | 167 | 0.030 |
Why?
|
| Hernia, Ventral | 1 | 2017 | 25 | 0.030 |
Why?
|
| Cyclin E | 2 | 2007 | 28 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2008 | 888 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 264 | 0.030 |
Why?
|
| Animals, Genetically Modified | 1 | 1997 | 183 | 0.030 |
Why?
|
| Cyclin B | 2 | 2006 | 18 | 0.030 |
Why?
|
| Genetic Engineering | 1 | 1997 | 116 | 0.030 |
Why?
|
| Breast Neoplasms, Male | 1 | 1997 | 31 | 0.030 |
Why?
|
| Serum Albumin | 1 | 2017 | 128 | 0.030 |
Why?
|
| Models, Economic | 1 | 2017 | 62 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2007 | 79 | 0.030 |
Why?
|
| Shock, Septic | 1 | 2017 | 105 | 0.030 |
Why?
|
| Molecular Sequence Data | 4 | 2005 | 3030 | 0.030 |
Why?
|
| Atrophy | 1 | 2017 | 124 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2010 | 693 | 0.030 |
Why?
|
| Body Composition | 1 | 2016 | 71 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 1999 | 961 | 0.030 |
Why?
|
| Pituitary Neoplasms | 1 | 1997 | 69 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 795 | 0.030 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1997 | 104 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 407 | 0.030 |
Why?
|
| Capecitabine | 1 | 2016 | 93 | 0.030 |
Why?
|
| Zonula Occludens-2 Protein | 3 | 2000 | 11 | 0.030 |
Why?
|
| Data Collection | 1 | 2017 | 377 | 0.030 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 205 | 0.030 |
Why?
|
| Cystadenoma, Mucinous | 1 | 1995 | 7 | 0.030 |
Why?
|
| Cystadenoma, Serous | 1 | 1995 | 16 | 0.030 |
Why?
|
| Butadienes | 2 | 2005 | 34 | 0.030 |
Why?
|
| RNA Helicases | 1 | 1996 | 35 | 0.030 |
Why?
|
| Flavonoids | 2 | 2006 | 85 | 0.030 |
Why?
|
| Mice | 5 | 2012 | 11949 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2015 | 67 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2017 | 361 | 0.030 |
Why?
|
| Heterografts | 1 | 2015 | 105 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1996 | 154 | 0.030 |
Why?
|
| Cost Control | 1 | 2015 | 45 | 0.030 |
Why?
|
| Keratin-19 | 1 | 2014 | 10 | 0.030 |
Why?
|
| Nitriles | 2 | 2005 | 156 | 0.030 |
Why?
|
| Mice, Nude | 2 | 2008 | 819 | 0.030 |
Why?
|
| Cystadenoma | 1 | 1994 | 19 | 0.030 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2016 | 176 | 0.030 |
Why?
|
| Proton Pump Inhibitors | 1 | 2015 | 34 | 0.030 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2014 | 34 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2014 | 67 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 93 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2015 | 85 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2014 | 79 | 0.030 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2014 | 8 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2015 | 168 | 0.030 |
Why?
|
| Perioperative Care | 1 | 2016 | 171 | 0.030 |
Why?
|
| Gene Expression | 2 | 2015 | 1313 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 1727 | 0.030 |
Why?
|
| Mastectomy | 1 | 1996 | 252 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2016 | 263 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 789 | 0.030 |
Why?
|
| Surgical Mesh | 1 | 2015 | 125 | 0.030 |
Why?
|
| Breast | 1 | 1996 | 289 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2014 | 301 | 0.030 |
Why?
|
| Bone Density Conservation Agents | 1 | 2014 | 42 | 0.030 |
Why?
|
| DNA | 2 | 2010 | 1314 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2016 | 776 | 0.030 |
Why?
|
| Mammography | 1 | 1996 | 468 | 0.030 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 1993 | 42 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2014 | 209 | 0.030 |
Why?
|
| Antigen-Antibody Complex | 1 | 1993 | 87 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2014 | 898 | 0.030 |
Why?
|
| Jejunostomy | 1 | 2012 | 14 | 0.030 |
Why?
|
| Ligation | 1 | 2012 | 53 | 0.030 |
Why?
|
| Gastric Emptying | 1 | 2012 | 25 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2019 | 1384 | 0.030 |
Why?
|
| Blood Sedimentation | 1 | 2012 | 13 | 0.030 |
Why?
|
| Synovial Membrane | 1 | 2012 | 28 | 0.030 |
Why?
|
| Celiac Artery | 1 | 2012 | 25 | 0.030 |
Why?
|
| Immunoblotting | 1 | 1993 | 272 | 0.030 |
Why?
|
| Rats | 3 | 2005 | 4061 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2015 | 455 | 0.020 |
Why?
|
| Bone Resorption | 1 | 2012 | 42 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 604 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2005 | 1242 | 0.020 |
Why?
|
| Enteral Nutrition | 1 | 2012 | 105 | 0.020 |
Why?
|
| Cricetinae | 2 | 2005 | 560 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2012 | 49 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2012 | 86 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2012 | 222 | 0.020 |
Why?
|
| Adiposity | 1 | 2012 | 76 | 0.020 |
Why?
|
| Mitomycin | 1 | 2011 | 29 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2012 | 196 | 0.020 |
Why?
|
| Anastomotic Leak | 1 | 2012 | 104 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 850 | 0.020 |
Why?
|
| Benzodiazepines | 1 | 2011 | 68 | 0.020 |
Why?
|
| Eye Proteins | 1 | 2012 | 128 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 285 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 1695 | 0.020 |
Why?
|
| Validation Studies as Topic | 1 | 2010 | 17 | 0.020 |
Why?
|
| Intestinal Perforation | 1 | 1990 | 36 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2011 | 279 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2010 | 126 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 2422 | 0.020 |
Why?
|
| Metaplasia | 1 | 2009 | 37 | 0.020 |
Why?
|
| Forecasting | 1 | 2011 | 306 | 0.020 |
Why?
|
| Obesity | 1 | 2016 | 979 | 0.020 |
Why?
|
| Sphincterotomy, Endoscopic | 1 | 2009 | 8 | 0.020 |
Why?
|
| Cause of Death | 1 | 2010 | 270 | 0.020 |
Why?
|
| CD11 Antigens | 1 | 2009 | 15 | 0.020 |
Why?
|
| Radiation Injuries | 1 | 1990 | 159 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2009 | 90 | 0.020 |
Why?
|
| Receptors, Androgen | 1 | 2009 | 119 | 0.020 |
Why?
|
| Masoprocol | 1 | 2008 | 3 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2009 | 95 | 0.020 |
Why?
|
| Thymidine | 1 | 2008 | 59 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2010 | 303 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2005 | 2077 | 0.020 |
Why?
|
| Periodic Acid-Schiff Reaction | 1 | 2008 | 6 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2008 | 10 | 0.020 |
Why?
|
| Pelvic Exenteration | 1 | 2008 | 5 | 0.020 |
Why?
|
| Quality of Life | 1 | 2017 | 1693 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 357 | 0.020 |
Why?
|
| Intestinal Fistula | 1 | 2008 | 31 | 0.020 |
Why?
|
| Perineum | 1 | 2008 | 36 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 2370 | 0.020 |
Why?
|
| Mice, Transgenic | 2 | 2005 | 1583 | 0.020 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 2007 | 11 | 0.020 |
Why?
|
| Professional Practice | 1 | 2008 | 45 | 0.020 |
Why?
|
| Tomography, Emission-Computed | 1 | 2008 | 102 | 0.020 |
Why?
|
| Abdominal Cavity | 1 | 2008 | 18 | 0.020 |
Why?
|
| Gastric Outlet Obstruction | 1 | 2007 | 10 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 1993 | 807 | 0.020 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1990 | 241 | 0.020 |
Why?
|
| Genes, bcl-2 | 1 | 2007 | 15 | 0.020 |
Why?
|
| Caspase 7 | 1 | 2007 | 15 | 0.020 |
Why?
|
| Cholestasis | 1 | 2007 | 45 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2007 | 27 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2007 | 25 | 0.020 |
Why?
|
| Caspase 9 | 1 | 2007 | 49 | 0.020 |
Why?
|
| Asthenia | 1 | 2007 | 3 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2007 | 36 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2007 | 46 | 0.020 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2007 | 37 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2010 | 426 | 0.020 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2007 | 9 | 0.020 |
Why?
|
| Dactinomycin | 1 | 2007 | 35 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2007 | 53 | 0.020 |
Why?
|
| cdc25 Phosphatases | 1 | 2006 | 19 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2009 | 472 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2007 | 162 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2008 | 997 | 0.020 |
Why?
|
| Surgical Wound Dehiscence | 1 | 1987 | 37 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2008 | 491 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2007 | 76 | 0.020 |
Why?
|
| CDC2 Protein Kinase | 1 | 2006 | 46 | 0.020 |
Why?
|
| Vagina | 1 | 2008 | 176 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2012 | 2042 | 0.020 |
Why?
|
| Cyclin B1 | 1 | 2006 | 18 | 0.020 |
Why?
|
| Headache | 1 | 2007 | 74 | 0.020 |
Why?
|
| Maleimides | 1 | 2006 | 26 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2006 | 70 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2006 | 77 | 0.020 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2006 | 42 | 0.020 |
Why?
|
| Vomiting | 1 | 2008 | 196 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2008 | 1095 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2008 | 605 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2007 | 697 | 0.020 |
Why?
|
| Nitrobenzenes | 1 | 2005 | 12 | 0.020 |
Why?
|
| Nitrosamines | 1 | 2005 | 8 | 0.020 |
Why?
|
| Base Sequence | 2 | 1999 | 2329 | 0.020 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2005 | 33 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2007 | 340 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2005 | 270 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2009 | 705 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2005 | 85 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 2006 | 267 | 0.020 |
Why?
|
| Androstadienes | 1 | 2005 | 73 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2005 | 111 | 0.020 |
Why?
|
| Disease Management | 1 | 2007 | 333 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2005 | 104 | 0.020 |
Why?
|
| Carcinogens | 1 | 2005 | 111 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2005 | 176 | 0.020 |
Why?
|
| Transfection | 1 | 2007 | 910 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2007 | 558 | 0.010 |
Why?
|
| Quinolines | 1 | 2005 | 87 | 0.010 |
Why?
|
| PPAR gamma | 1 | 2005 | 73 | 0.010 |
Why?
|
| Random Allocation | 1 | 2005 | 327 | 0.010 |
Why?
|
| Indoles | 1 | 2006 | 306 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2005 | 397 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2005 | 419 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2007 | 728 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2005 | 309 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2005 | 3431 | 0.010 |
Why?
|
| Pregnancy Complications | 1 | 2007 | 344 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2007 | 538 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2005 | 671 | 0.010 |
Why?
|
| Cell Survival | 1 | 2006 | 987 | 0.010 |
Why?
|
| Sulfonamides | 1 | 2005 | 320 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 651 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2006 | 589 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 1161 | 0.010 |
Why?
|
| Cell Line | 1 | 2006 | 2505 | 0.010 |
Why?
|
| Thyroid Gland | 1 | 2002 | 281 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2007 | 1553 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2005 | 2895 | 0.010 |
Why?
|
| Biomarkers | 1 | 2006 | 1800 | 0.010 |
Why?
|
| Vulvar Neoplasms | 1 | 2000 | 19 | 0.010 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 1999 | 11 | 0.010 |
Why?
|
| Palpation | 1 | 1999 | 18 | 0.010 |
Why?
|
| Coloring Agents | 1 | 1999 | 66 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2000 | 281 | 0.010 |
Why?
|
| Pregnancy | 1 | 2007 | 3070 | 0.010 |
Why?
|
| Introns | 1 | 2000 | 302 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1999 | 258 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1999 | 222 | 0.010 |
Why?
|
| Axilla | 1 | 1999 | 104 | 0.010 |
Why?
|
| Exons | 1 | 2000 | 453 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2005 | 1259 | 0.010 |
Why?
|
| Medical Staff, Hospital | 1 | 1999 | 109 | 0.010 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 1997 | 67 | 0.010 |
Why?
|
| Gynecomastia | 1 | 1997 | 8 | 0.010 |
Why?
|
| Mastectomy, Modified Radical | 1 | 1997 | 6 | 0.010 |
Why?
|
| Genetic Techniques | 1 | 1997 | 73 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1997 | 511 | 0.010 |
Why?
|
| Heart Failure | 1 | 2007 | 1270 | 0.010 |
Why?
|
| Recurrence | 1 | 1999 | 1162 | 0.010 |
Why?
|
| RNA, Double-Stranded | 1 | 1996 | 23 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1996 | 153 | 0.010 |
Why?
|
| DEAD-box RNA Helicases | 1 | 1996 | 64 | 0.010 |
Why?
|
| eIF-2 Kinase | 1 | 1995 | 48 | 0.010 |
Why?
|
| Precancerous Conditions | 1 | 1996 | 201 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 1993 | 776 | 0.000 |
Why?
|